Adenosine Receptors in Health and Disease

Advances in Pharmacology

Volumn 61, Issue , 2011, Pages 41-75

  Gessi, Stefania ^a   Merighi, Stefania ^a   Varani, Katia ^a   Borea, Pier Andrea ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Adenosine receptors; Cancer; Cardiovascular diseases; Inflammation; Neurologic diseases; Respiratory disorders

Indexed keywords

2 (1 OCTYNYL)ADENOSINE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; APADENOSON; BINODENOSON; CAPADENOSON; CVT 3619; CVT 6883; CYCLIC AMP DEPENDENT PROTEIN KINASE; DERENOFYLLINE; DOXOFYLLINE; GS 6201; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; ISTRADEFYLLINE; MNI 420; N METHYL DEXTRO ASPARTIC ACID; PJ 875; PRELADENANT; REGADENOSON; ROLOFYLLINE; SELODENOSON; SONEDENOSON; ST 1535; SYN 115; T 62; TECADENOSON; THEOPHYLLINE; TONAPOFYLLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ASTHMA; BOOK; BRADYCARDIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; GASTROINTESTINAL TRACT; GLAUCOMA; HEART BLOCK; HEART FAILURE; HUMAN; HUNTINGTON CHOREA; HYPERPOLARIZATION; HYPERTENSION; IN VIVO STUDY; INFLAMMATION; ISCHEMIC PRECONDITIONING; KIDNEY FAILURE; LIPOPROTEIN DEFICIENCY; NEOPLASM; NERVOUS SYSTEM; NEUROPATHIC PAIN; NONHUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; VASCULARIZATION;

EID: 79955961691     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385526-8.00002-3     Document Type: Chapter

References (170)

1. 2A receptor is a unique angiogenic target of HIF-2alpha in pulmonary endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:10684-10689.
2. Avni I., Garzozi H.J., Barequet I.S., Segev F., Varssano D., Sartani G., et al. Treatment of dry eye syndrome with orally administered CF101: Data from a phase 2 clinical trial. Ophthalmology 2010, 117:1287-1293.
3. (3) receptor antagonists. Trends in Pharmacological Sciences 2000, 21:456-459.
4. Baraldi P.G., Tabrizi M.A., Gessi S., Borea P.A. Adenosine receptor antagonists: Translating medicinal chemistry and pharmacology into clinical utility. Chemical Reviews 2008, 108:238-263.
5. 1 -adenosine receptor. Bioorganic & Medicinal Chemistry Letters 2000, 10:1953-1957.
6. 3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. International Journal of Oncology 2008, 33:287-295.
7. Bayes M. Gateways to clinical trials. Methods and Findings in Experimental and Clinical Pharmacology 2007, 29:153-173.
8. 2A adenosine receptor mediates coronary vasodilation. The Journal of Pharmacology and Experimental Therapeutics 1998, 284:1066-1073.
9. 2B receptor. European Journal of Immunology 2008, 38:1610-1620.
10. Bingham T.C., Fisher E.A., Parathath S., Reiss A.B., Chan E.S., Cronstein B.N. A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux. Journal of Leukocyte Biology 2010, 87:683-690.
11. 3 adenosine receptor. Circulation Research 2002, 91:165-172.
12. Blackburn M.R., Vance C.O., Morschl E., Wilson C.N. Adenosine receptors and inflammation. Handbook of Experimental Pharmacology 2009, 193:215-269.
13. Boison D. Adenosine as a neuromodulator in neurological diseases. Current Opinion in Pharmacology 2007, 8:1-6.
14. Borsellino G., Kleinewietfeld M., Di Mitri D., Sternjak A., Diamantini A., Giometto R., et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-1232.
15. 1 receptor in bronchial biopsies from asthmatic subjects. European Respiratory Journal 2008, 31:1-9.
16. Brown R.A., Spina D., Page C.P. Adenosine receptors and asthma. British Journal of Pharmacology 2008, 153:S446-S456.
17. Chan E.S., Cronstein B.N. Methotrexate-How does it really work?. Nature Reviews. Rheumatology 2010, 6:175-178.
18. 2A receptors play a role in the pathogenesis of hepatic cirrhosis. British Journal of Pharmacology 2006, 148:1144-1155.
19. 3 receptors. Science 2006, 314:1792-1795.
20. Chen S.W., Park S.W., Kim M., Brown K.M., D'Agati V.D., Lee H.T. Human heat shock protein 27 overexpressing mice are protected against hepatic ischemia and reperfusion injury. Transplantation 2009, 87:1478-1487.
21. Ciruela F., Albergaria C., Soriano A., Cuffí L., Carbonell L., Sánchez S., et al. Adenosine receptors interacting proteins (ARIPs): Behind the biology of adenosine signaling. Biochimica et Biophysica Acta 2010, 1798:9-20.
22. 2B adenosine receptors can change their spots. British Journal of Pharmacology 2010, 159:1595-1597.
23. Deaglio S., Dwyer K.M., Gao W., Friedman D., Usheva A., Erat A., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. The Journal of Experimental Medicine 2007, 204:1257-1265.
24. 1 adenosine receptor agonist devoid of cardiovascular effects: Comparison with nicotinic acid. The Journal of Pharmacology and Experimental Therapeutics 2007, 321:327-333.
25. 1 -adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents. American Journal of Physiology. Endocrinology and Metabolism 2007, 292:E1358-E1363.
26. Driver A.G., Kukoly C.A., Ali S., Mustafa S.J. Adenosine in bronchoalveolar lavage fluid in asthma. The American Review of Respiratory Disease 1993, 148:91-97.
27. Eisenach J.C., Hood D.D., Curry R. Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans. Anesthesiology 2002, 96:29-34.
28. 2B adenosine receptor during gastrointestinal ischemia and inflammation. Expert Opinion on Therapeutic Targets 2009, 13:1267-1277.
29. Ernens I., Léonard F., Vausort M., Rolland-Turner M., Devaux Y., Wagner D.R. Adenosine up-regulates vascular endothelial growth factor in human macrophages. Biochemical and Biophysical Research Communications 2010, 392:351-356.
30. 1 receptors mediate mobilization of calcium in human bronchial smooth muscle cells. American Journal of Respiratory Cell and Molecular Biology 2006, 35:496-502.
31. 1 -adenosine receptor and evidence of receptor homogeneity in adipocytes. The Journal of Pharmacology and Experimental Therapeutics 2006, 317:676-684.
32. 3 adenosine receptor: Sensitivity to hypoxic neurodegeneration. Cellular and Molecular Neurobiology 2003, 23:431-447.
33. 2B receptor activation. American Journal of Physiology. Renal Physiology 2010, 299:F310-F315.
34. 2B receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. Journal of Clinical Investigation 1995, 96:1979-1986.
35. 2B receptors: A novel therapeutic target in asthma?. Trends in Pharmacological Sciences 1998, 1998(19):148-153.
36. Fishman P., Bar-Yehuda S., Madi L., Rath-Wolfson L., Ochaion A., Cohen S., et al. The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Research & Therapy 2006, 8:R33.
37. 3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene 2004, 23:2465-2471.
38. Fishman P., Bar-Yehuda S., Synowitz M., Powell J.D., Klotz K.N., Gessi S., et al. Adenosine receptors and cancer. Handbook of Experimental Pharmacology 2009, 193:399-441.
39. Fredholm B.B. Adenosine receptors as drug targets. Experimental Cell Research 2010, 316:1284-1288.
40. Fredholm B.B., IJzerman A.P., Jacobson K.A., Kloz K.N., Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacological Reviews 2001, 53:527-552.
41. 2B receptors to inflammatory parameters of experimental colitis. Journal of Immunology 2009, 182:4957-4964.
42. 1 -adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function. Circulation 2006, 114:2240-2250.
43. Gan T.J., Habib A.S. Adenosine as a non-opioid analgesic in the perioperative setting. Anesthesia and Analgesia 2007, 105:487-494.
44. 3 adenosine receptors attenuates lung ischemia-reperfusion injury. The Journal of Thoracic and Cardiovascular Surgery 2010, 140:440-446.
45. 3 adenosine receptor. Journal of Pharmacology and Experimental Therapeutics 2006, 319:1200-1210.
46. 3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clinical Cancer Research 2004, 10:5895-5901.
47. Gessi S., Fogli E., Sacchetto V., Merighi S., Varani K., Preti D., et al. Adenosine modulates HIF-1alpha, VEGF, IL-8, and foam cell formation in a human model of hypoxic foam cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 30:90-97.
48. Gessi S., Merighi S., Sacchetto V., Simioni C., Borea P.A. Adenosine receptors and cancer. Biochimica et Biophysica Acta 2010, in press.
49. 3 adenosine subtype. Journal of Cellular Physiology 2007, 211:826-836.
50. 3 adenosine receptor: An enigmatic player in cell biology. Pharmacology & Therapeutics 2008, 117:123-140.
51. 3 adenosine receptors. Biochemical Pharmacology 2010, 79:1483-1495.
52. 3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: A pharmacological and biochemical study. Molecular Pharmacology 2002, 61:415-424.
53. 2A adenosine receptors in human peripheral blood cells. British Journal of Pharmacology 2000, 129:2-11.
54. 1 receptor on pain-related behavior in normal and nerve-injured rats. Brain Research 2010, 1361:23-30.
55. Grenz A., Zhang H., Eckle T., Mittelbronn M., Wehrmann M., Kohle C., et al. Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia. Journal of the American Society of Nephrology 2007, 18:833-845.
56. Ham M., Mizumori M., Watanabe C., Wang J., Inoue T., Nakano T., et al. Endogenous luminal surface adenosine signaling regulates duodenal bicarbonate secretion in rats. The Journal of Pharmacology and Experimental Therapeutics 2010, 335:607-613.
57. 2B adenosine receptors in immunity and inflammation. Trends in Immunology 2009, 30:263-270.
58. Haskó G., Linden J., Cronstein B., Pacher P. Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. Nature Reviews. Drug Discovery 2008, 7:759-770.
59. 2A receptors in inflammation and injury: Lessons learned from transgenic animals. Journal of Leukocyte Biology 2008, 83:447-455.
60. Haskó G., Pacher P., Deitch E.A., Vizi E.S. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacology & Therapeutics 2007, 113:264-275.
61. Haskó G., Pacher P., Vizi E.S., Illes P. Adenosine receptor signaling in the brain immune system. Trends in Pharmacological Sciences 2005, 26:511-516.
62. 2A receptor activation protects CD4+ T lymphocytes against activation-induced cell death. The FASEB Journal 2010, 24:2631-2640.
63. 1 receptor antagonists in clinical research and development. Kidney International 2010, 78:438-445.
64. Hu H., Lu W., Zhang M., Zhang X., Argall A.J., Patel S., et al. Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. Experimental Eye Research 2010, 91:425-432.
65. 3 adenosine receptor-mediated cardioprotection. Autonomic & Autacoid Pharmacology 2009, 29:97-104.
66. Inoue Y., Tanaka H., Sumi Y., Woehrle T., Chen Y., Hirsh M.I., et al. A3 adenosine receptor inhibition improves the efficacy of hypertonic saline resuscitation. Shock 2010, 35:178-183.
67. 3 receptors: Novel ligands and paradoxical effects. Trends in Pharmacological Sciences 1998, 19:184-191.
68. Jacobson K.A., Gao Z.G. Adenosine receptors as therapeutic targets. Nature Reviews 2006, 5:247-264.
69. 1 receptor desensitization and recovery. American Journal of Physiology. Cell Physiology 2010, 298:C56-C65.
70. 3 receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. Neoplasia 2009, 11:1132-1145.
71. 2A antagonists, and Parkinson's disease. Parkinsonism & Related Disorders 2009, 15:406-413.
72. Kälin R.E., Bänziger-Tobler N.E., Detmar M., Brändli A.W. An in vivo chemical library screen in Xenopus tadpoles reveals novel pathways involved in angiogenesis and lymphangiogenesis. Blood 2009, 114:1110-1122.
73. 1 Rs) play a critical role in osteoclast formation and function. The FASEB Journal 2010, 24:2325-2333.
74. Kara F.M., Doty S.B., Boskey A., Goldring S., Zaidi M., Fredholm B.B., et al. Adenosine A(1) receptors regulate bone resorption in mice: Adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. Arthritis and Rheumatism 2010, 62:534-541.
75. 3 adenosine receptors protects the ischemic reperfused myocardium via recruitment of PI3K-AKT-iNOS cell survival pathway. Circulation 2006, 114:II_1204.
76. 3 adenosine receptor activation via 2-Cl-IBMECA protects the myocardium via recruitment of PI3K-AKT-iNOS intracellular signalling pathway during reperfusion. Journal of Molecular and Cellular Cardiology 2008, 44:738.
77. 2A receptor agonist for myocardial perfusion imaging, on coronary blood flow velocity in conscious patients. Circulation 2006, 114:2780.
78. 1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handbook of experimental pharmacology 2009, (Vol. 193:25-58. Springer-Verlag, Berlin, Heidelberg. C.N. Wilson, S.J. Mustafà (Eds.).
79. 1 adenosine receptor knockout mice reduces renal ischemia-reperfusion injury. Kidney International 2009, 75:809-823.
80. 3 adenosine receptor antagonist, truncated Thio-Cl-IB-MECA, induces apoptosis in T24 human bladder cancer cells. Anticancer Research 2010, 30:2823-2830.
81. Koda K., Salazar-Rodriguez M., Corti F., Chan N.Y., Estephan R., Silver R.B., et al. Aldehyde dehydrogenase activation prevents reperfusion arrhythmias by inhibiting local renin release from cardiac mast cells. Circulation 2010, 122:771-781.
82. 1 adenosine receptor abolishes heart-rate slowing effects of intravascular adenosine in vivo. PLoS One 2009, 4:e6784.
83. 2A adenosine receptor in rats. Journal of Gastroenterology 2009, 44:419-425.
84. 2B adenosine receptor gene deletion attenuates murine colitis. Gastroenterology 2008, 135:861-870.
85. 2B receptor expression is post-transcriptionally regulated by microRNA. The Journal of Biological Chemistry 2010, 285:18184-18190.
86. 2B receptor in hypoxia. The FASEB Journal 2006, 20:2242-2250.
87. 3 adenosine receptor. The Journal of Pharmacology and Experimental Therapeutics 2006, 317:172-180.
88. 2B -dependent signaling during early reperfusion. Journal of Molecular and Cellular Cardiology 2007, 43:262-271.
89. 2B agonists by protein kinase C. American Journal of Physiology. Heart and Circulatory Physiology 2008, 295:H1288-H1295.
90. 3 receptor suppresses lipopolysaccaride-induced TNF-α production through inhibition of PI-3-kinase/Akt and NF-κB activation in murine BV2 microglial cells. Neuroscience Letters 2006, 396:1-6.
91. 3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 2006, 291:R959-R969.
92. 2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Annals of Neurology 2008, 63:295-302.
93. Linden J. Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection. Annual Review of Pharmacology and Toxicology 2001, 41:775-787.
94. Linden J. Adenosine in tissue protection and tissue regeneration. Molecular Pharmacology 2005, 67:1385-1387.
95. Linden J. Purinergic chemotaxis. Science 2006, 314:1689-1690.
96. 3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: Involvement of nuclear factor-kappaB in mediating receptor level. The Journal of Rheumatology 2007, 34:20-26.
97. 3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-α release by reducing calcium-dependent activation of nuclear factor-kB and extracellular signal-regulated kinase 1/2. The Journal of Pharmacology and Experimental Therapeutics 2006, 316:71-78.
98. 3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Critical Care 2006, 10:R65.
99. 2A adenosine receptor on the profile of chemokines produced by neutrophils. The FASEB Journal 2006, 20:187-189.
100. 3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. The Journal of Biological Chemistry 2005, 280:19516-19526.
101. Merighi S., Benini A., Mirandola P., Gessi S., Varani K., Leung E., et al. Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochemical Pharmacology 2006, 72:19-31.
102. Merighi S., Benini A., Mirandola P., Gessi S., Varani K., Leung E., et al. Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Molecular Pharmacology 2007, 72:162-172.
103. Merighi S., Benini A., Mirandola P., Gessi S., Varani K., Simioni C., et al. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Molecular Pharmacology 2007, 72:395-406.
104. Merighi S., Mirandola P., Varani K., Gessi S., Leung E., Baraldi P.G., et al. A glance at adenosine receptors: Novel target for antitumor therapy. Pharmacology & Therapeutics 2003, 100:31-48.
105. 3 adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia 2009, 11:1064-1073.
106. 2B adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts. American Journal of Physiology. Heart and Circulatory Physiology 2010, 299:H1262-H1264.
107. 2A adenosine receptor enhances pulmonary inflammation, mucin production, and angiogenesis in adenosine deaminase-deficient mice. American Journal of Physiology. Lung Cellular and Molecular Physiology 2007, 293:753-761.
108. 3 receptor activation in thioglycollate-induced peritonitis. Arthritis Research & Therapy 2006, 8:R53.
109. 3 adenosine receptor signaling influences pulmonary inflammation and fibrosis. American Journal of Respiratory Cell and Molecular Biology 2008, 39:697-705.
110. 2A adenosine receptors in the T cell-mediated regulation of colitis. Journal of Immunology 2006, 177:2765-2769.
111. 2A receptor subtypes and protein kinase C pathways. The Journal of Pharmacology and Experimental Therapeutics 2010, 334:590-598.
112. 1 regulates polymorphonuclear cell trafficking and microvascular permeability in lipopolysaccharide-induced lung injury. Journal of Immunology 2010, 185:4374-4384.
113. Novitskiy S.V., Ryzhov S., Zaynagetdinov R., Goldstein A.E., Huang Y., Tikhomirov O.Y., et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 2008, 112:1822-1831.
114. Ohta A., Sitkovsky M. The adenosinergic immunomodulatory drugs. Current Opinion in Pharmacology 2009, 9:501-506.
115. 2B receptor cascade. Cardiovascular Research 2006, 70:308-314.
116. Polosa R., Blackburn M.R. Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease. Trends in Pharmacological Sciences 2009, 30:528-535.
117. Polosa R., Rorke S., Volgate S.T. Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Thorax 2002, 57:649-654.
118. 1 adenosine receptors in altered vascular responses and inflammation in an allergic mouse model of asthma. American Journal of Physiology. Heart and Circulatory Physiology 2010, 299:H81-H87.
119. Press N.J., Gessi S., Borea P.A., Polosa R. Therapeutic potential of adenosine receptor antagonists and agonists. Expert Opinion on Therapeutic Patents 2007, 17:979-991.
120. 2B receptors and enhances chloride secretion in kidney inner medullary collecting duct cells. Hypertension 2010, 55:1123-1128.
121. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacological Reviews 1998, 50:413-492.
122. Raman M., Chen W., Cobb M.H. Differential regulation and properties of MAPKs. Oncogene 2007, 26:3100-3112.
123. 1 adenosine receptors: State of the art and new horizons for drug development. Current Medicinal Chemistry 2010, 17:3488-3502.
124. Russo C., Arcidiacono G., Polosa R. Adenosine receptors: Promising targets for the development of novel therapeutics and diagnostics for asthma. Fundamental & Clinical Pharmacology 2006, 20:9-19.
125. 3 receptors. Journal of Immunology 1996, 156:3435-3442.
126. 3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. The Journal of Biological Chemistry 2000, 275:4429-4434.
127. 2B adenosine receptor dampens endotoxin-induced acute lung injury. Journal of Immunology 2010, 184:5271-5279.
128. 1 adenosine receptors. British Journal of Pharmacology 2009, 156:163-172.
129. Schnermann J., Briggs J.P. Tubuloglomerular feedback: Mechanistic insights from gene-manipulated mice. Kidney International 2008, 74:418-426.
130. 1 receptor-mediated inhibition of myocardial norepinephrine release involves neither phospholipase C nor protein kinase C but does involve adenylyl cyclase. Canadian Journal of Physiology and Pharmacology 2006, 84:573-577.
131. 2A receptors attenuates allograft rejection and alloantigen recognition. Journal of Immunology 2007, 178:4240-4249.
132. 1 adenosine receptor agonist regulates cardiac substrate utilization in insulin-resistant rats in vivo. The Journal of Pharmacology and Experimental Therapeutics 2009, 328:306-311.
133. 3 receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury. American Journal of Physiology. Heart and Circulatory Physiology 2005, 288:H2792-H2801.
134. 2A receptor antagonists and Parkinson's disease: State of the art and future directions. Current Pharmaceutical Design 2008, 14:1475-1789.
135. Sitkovsky M.V. T regulatory cells: Hypoxia-adenosinergic suppression and re-direction of the immune response. Trends in Immunology 2009, 30:102-108.
136. 2A receptors. Annual Review of Immunology 2004, 22:657-682.
137. 1 receptor antagonist for the treatment of heart failure. Expert Opinion on Pharmacotherapy 2009, 10:311-322.
138. Solenkova N.V., Solodushko V., Cohen M.V., Downey J.M. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. American Journal of Physiology. Heart and Circulatory Physiology 2006, 290:H441-H449.
139. Sowa N.A., Street S.E., Vihko P., Zylka M.J. Prostatic acid phosphatase reduces thermal sensitivity and chronic pain sensitization by depleting phosphatidylinositol 4,5-bisphosphate. The Journal of Neuroscience 2010, 30:10282-10293.
140. 2B adenosine receptor mediates cAMP responses to adenosine receptor agonists in human intestinal epithelia. The Journal of Biological Chemistry 1995, 270:2387-2394.
141. 2A adenosine receptor via a novel interacting protein, translin-associated protein X. Molecular Pharmacology 2006, 70:454-466.
142. Sun D., Samuelson L.C., Yang T., Huang Y., Paliege A., Saunders T., et al. Mediation of tubuloglomerular feedback by adenosine: Evidence from mice lacking adenosine 1 receptors. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:9983-9988.
143. Sun C.X., Young H.W., Molina J.G., Volmer J.B., Schnermann J., Blackburn M.R. A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. Journal of Clinical Investigation 2005, 115:35-43.
144. 2 . Cellular & Molecular Immunology 2010, 7:77-82.
145. 2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. Journal of Clinical Investigation 2006, 116:2173-2182.
146. Taliani S., La Motta C., Mugnaini L., Simorini F., Salerno S., Marini A.M., et al. Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: Inhibition of A3-mediated human glioblastoma cell proliferation. Journal of Medicinal Chemistry 2010, 53:3954-3963.
147. 2A receptor signalling in a mouse model of Huntington disease. Neurobiology of Disease 2006, 23:44-53.
148. Vallon V., Mühlbauer B., Osswald H. Adenosine and kidney function. Physiological Reviews 2006, 86:901-940.
149. Van Calker D.M., Muller M., Hamprecht B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. Journal of Neurochemistry 1979, 33:999-1005.
150. Varani K., Caramori G., Vincenzi F., Adcock I., Casolari P., Leung E., et al. Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2006, 173:398-406.
151. 2A adenosine receptors in chronic heart failure and cardiac transplantation. The FASEB Journal 2003, 17:280-282.
152. Varani K., Maniero S., Vincenzi F., Targa M., Stefanelli A., Maniscalco P., et al. A3 receptors are overexpressed in pleura from mesothelioma patients and reduce cell growth via Akt/NF-kB pathway. American Journal of Respiratory and Critical Care Medicine 2010, 183:522-530.
153. 3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. Arthritis and Rheumatism 2009, 60:2880-2891.
154. 2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. The FASEB Journal 2010, 24:587-598.
155. Varani K., Vincenzi F., Tosi A., Targa M., Masieri F.F., Ongaro A., et al. Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes. British Journal of Pharmacology 2010, 160:101-115.
156. 2B receptors begun after myocardial infarction prevents cardiac remodeling in rats. Circulation 2006, 114:1923-1932.
157. 2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 2010, 116:5010-5020.
158. 3 adenosine receptors lower mouse intraocular pressure and act across species. Experimental Eye Research 2010, 90:146-154.
159. 1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. Journal of Cardiac Failure 2010, 16:25-35.
160. Wilson C.N. Adenosine receptors and asthma in humans. British Journal of Pharmacology 2008, 155:475-486.
161. 3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. Current Eye Research 2005, 30:747-754.
162. 2B adenosine receptor in regulating platelet function. Journal of Thrombosis and Haemostasis 2010, 8:817-827.
163. 2B skews human dendritic cells to a Th2-stimulating phenotype under hypoxia. Immunology and Cell Biology 2010, 88:165-171.
164. 2B adenosine receptor protects against inflammation and excessive vascular adhesion. Journal of Clinical Investigation 2006, 116:1913-1923.
165. Yldiz G., Demiryurek A.T., Gumusel B., Lippton H. Ischemic preconditioning modulates ischemia-reperfusion injury in the rat lung: Role of adenosine receptors. European Journal of Pharmacology 2007, 556:144-150.
166. 3 adenosine receptor in rat retinal ganglion cells. Molecular Vision 2006, 12:937-948.
167. 3 adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells. Neurochemistry International 2010, 56:35-41.
168. 3 adenosine receptors prevent loss following P2X7 receptor stimulation. Journal of Neurochemistry 2006, 98:566-575.
169. 3 receptor reverses vascular hyporeactivity after hemorrhagic shock in rats. Acta Pharmacologica Sinica 2010, 31:413-420.
170. 1 receptor antagonist blunts urinary potassium excretion, but not renal hemodynamic effects, induced by carbonic anhydrase inhibitor in rats. The Journal of Pharmacology and Experimental Therapeutics 2006, 316:530-538.